| AASLD

Deep learning and the future of the Model for End‐Stage Liver Disease–sodium score

Read more about Deep learning and the future of the Model for End‐Stage Liver Disease–sodium score

Michael Cooper, Rahul G. Krishnan, Mamatha Bhat – 18 April 2022

Interaction of metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019

Read more about Interaction of metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019

Martín Uriel Vázquez‐Medina, Eira Cerda‐Reyes, Alberto Galeana‐Pavón, Carlos Enrique López‐Luna, Patty Marlen Ramírez‐Portillo, Gabriela Ibañez‐Cervantes, Julián Torres‐Vázquez, Cruz Vargas‐De‐León – 18 April 2022 – Patients with pre‐existing liver diseases are considered to have an increased risk of morbidity and mortality from any type of infection, including viruses.

Portal Hypertension Bleeding in Cirrhosis

Read more about Portal Hypertension Bleeding in Cirrhosis

This guidance provides a data-supported approach to risk stratification, diagnosis, and management of patients with cirrhosis and portal hypertension (PH).